Dr Reddy's Expands Global Footprint With Strategic US Pharma Partnership
Dr. Reddy's secures exclusive US rights for Cyclophosphamide injection from Ingenus Pharmaceuticals, sharing 50% of profits.
The company was informed by Dr Reddy’s Laboratories on
Wednesday about the licensing agreement with the US-based company Ingenus
Pharmaceuticals LLC, granting it exclusive rights in the US market to introduce
the cancer treatment drug Cyclophosphamide injection in the US market.
According to a regulatory filing by Dr Reddy's, Dr. Reddy’s Laboratories Inc.,
a fully-owned subsidiary, has signed an agreement with a Delaware limited
liability company to commercialize Cyclophosphamide injection RTD (500mg/2.5ml,
1g/5ml, 2g/10ml).
As part of the deal, Dr Reddy’s will pay Ingenus only 50% of
the calculated profit share of the sales of the drug in the US market. The
company mentioned that “No other consideration (is) payable. The NDA covering
the product will be assigned to Dr Reddy’s USA. The parties will enter into a
commercial supply agreement pursuant to which Ingenus will supply the product
to Dr Reddy’s USA.”
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Discussion